Table 3 Clinical Characteristics. SCD-related clinical characteristics for patients: Children of parent participants (Group 1) and adolescent patient participants (Group 2) patients are both included here. Patients who were a part of a dyad are only represented once
Patient Characteristics (n = 18) | |
|---|---|
Genotype, n (%) | |
HbSS or HbS-β0 thalassemia | 18 (100) |
Transfusion Type, n (%) | |
Simple | 11 (61.1) |
Erythracytapheresis | 5 (27.8) |
Partial manual exchange | 2 (11.1) |
Duration of CTT, median years (IQR) | 6.8 (4.3–9.8) |
Indication for CTT, n (%) | |
Abnormal TCD | 5 (27.8) |
Overt or silent stroke | 12 (66.6) |
Splenic sequestration | 1 (5.6) |
Chelation type, n (%) | |
None | 3 (16.7) |
Deferasirox | 15 (83.3) |
Taking hydroxyurea, n (%) | 3 (16.7) |
Current or prior CTT-related complications, n (%) | |
Iron overload | 17 (94.4) |
Red cell antibodies | 9 (50.0) |
Port complications | 3 (16.7) |
Renal complications | 2 (11.1) |